Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Clopidogrel: who, when, and how?

Christopher P Cannon1

  • 1Thrombolysis in Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

Reviews in Cardiovascular Medicine
|October 17, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease.

The American journal of medicine·2013
Same author

Evaluation of lipids, drug concentration, and safety parameters following cessation of treatment with the cholesteryl ester transfer protein inhibitor anacetrapib in patients with or at high risk for coronary heart disease.

The American journal of cardiology·2013
Same author

Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial.

Circulation·2013
Same author

Predictors of long-term adherence to evidence-based cardiovascular disease medications in outpatients with stable atherothrombotic disease: findings from the REACH Registry.

Clinical cardiology·2013
Same author

Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes.

Circulation·2013
Same author

Lipoprotein(a) for risk assessment in patients with established coronary artery disease.

Journal of the American College of Cardiology·2013
Same journal

The Influence of Congenital Heart Defect Repair Through a Right Subaxillary Thoracotomy on Postoperative Pulmonary Function and Prognosis in Small Infants.

Reviews in cardiovascular medicine·2026
Same journal

Left Ventricular Hypertrabeculation: Historical Evolution, Diagnostic Pitfalls, and a Pragmatic Clinical Approach.

Reviews in cardiovascular medicine·2026
Same journal

Study on the Role and Mechanism of γδ T Cells in Atherosclerosis Under a High-Fat Diet.

Reviews in cardiovascular medicine·2026
Same journal

The Role of Stress Granules in Cardiovascular Diseases.

Reviews in cardiovascular medicine·2026
Same journal

Computed Tomography-Based Radiomics Provides New Insights Into Associations Between Pericoronary Fat Characteristics and Low-Density Lipoprotein Cholesterol.

Reviews in cardiovascular medicine·2026
Same journal

Association of Triglyceride-Glucose Index With In-Hospital Malignant Arrhythmias in Older Patients With Diabetes Mellitus and Left Ventricular Aneurysm: A Retrospective Study.

Reviews in cardiovascular medicine·2026
See all related articles

Clopidogrel plus aspirin significantly reduces adverse events in acute coronary syndromes. Early treatment, especially before percutaneous coronary intervention (PCI), and up to one year of therapy improve patient outcomes.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Acute coronary syndromes (ACS) are a major cause of cardiovascular morbidity and mortality.
  • Clopidogrel is an antiplatelet medication used in ACS management.
  • Uncertainties remain regarding optimal clopidogrel use in clinical practice.

Purpose of the Study:

  • To review clinical trial data on clopidogrel use in patients with ACS.
  • To address questions regarding patient selection, timing, dosage, and duration of clopidogrel therapy.

Main Methods:

  • Analysis of results from completed randomized controlled trials assessing clopidogrel in ACS patients.
  • Evaluation of treatment strategies including loading dose, timing relative to percutaneous coronary intervention (PCI), and duration of therapy.

Related Experiment Videos

Main Results:

  • Clopidogrel plus aspirin demonstrated a reduction in the composite endpoint of death, myocardial infarction, or stroke compared to aspirin alone in ACS patients.
  • Early initiation of clopidogrel (over 6 hours before PCI) was linked to decreased risk of death and recurrent ischemic events.
  • A 600-mg loading dose of clopidogrel before PCI showed proven benefits.
  • Long-term treatment with clopidogrel for up to 1 year post-PCI is recommended by guidelines.

Conclusions:

  • Clopidogrel in combination with aspirin offers significant benefits for ACS patients.
  • Optimal timing (early, pre-PCI) and duration (up to 1 year) of clopidogrel therapy are crucial for maximizing patient outcomes.
  • Evidence supports the use of a 600-mg loading dose prior to PCI.